A Randomized, Double Blind, Placebo-controlled, Parallel Group Study to Determine the Efficacy, the Duration of Action, and Safety of Latanoprost in Patients With Meniere's Disease

Trial Profile

A Randomized, Double Blind, Placebo-controlled, Parallel Group Study to Determine the Efficacy, the Duration of Action, and Safety of Latanoprost in Patients With Meniere's Disease

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Jun 2016

At a glance

  • Drugs Latanoprost (Primary)
  • Indications Meniere's disease
  • Focus Therapeutic Use
  • Sponsors Synphora
  • Most Recent Events

    • 19 Jun 2016 Status changed from active, no longer recruiting to completed.
    • 16 Mar 2016 Phase of the study changed from phase II/III to phase II, according to ClinicalTrials.gov record.
    • 16 Mar 2016 Planned primary completion date changed from 1 Oct 2014 to 1 May 2016, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top